Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ZBIO News 22 December 2025 - 6 January 2026

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.
6 January 2026
··
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.
30 December 2025
·
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat+1 The timing isn’t subtle: Zenas is approaching a pivotal clinical-data moment for its lead asset obexelimab, and Wall Street research desks are increasingly framing the stock as a near-term catalyst setup—high potential reward, high potential whiplash. Below is a full roundup of the news,
22 December 2025
·

Stock Market Today

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

7 February 2026
GE Vernova shares jumped 5.6% to $779.35 Friday as Wall Street rallied and the company reported 1.1 GW of U.S. wind repower orders for 2025. The company also closed its $5.3 billion purchase of the remaining Prolec GE stake and completed a $2.6 billion senior notes offering. Investors await next week’s U.S. jobs and inflation data.
Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

7 February 2026
Citigroup shares rose 6% to $122.69 at Friday’s close after a Reuters report said executives are more optimistic about completing key consent orders this year. Citi also announced a $2.3 billion preferred stock redemption and a matching program for employee “Trump Accounts.” Investors await next week’s U.S. economic data and Citi conference appearances.
Go toTop